Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ASP2138 |
Trade Name | |
Synonyms | ASP-2138|ASP 2138 |
Drug Descriptions |
ASP2138 is a bispecific antibody that targets Claudin 18.2 (CLDN18.2) expressed on tumor cells and CD3 on T-cells, which potentially leads to cytotoxic killing of tumor cells expressing CLDN18.2, enhanced antitumor immune response, and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 2962). |
DrugClasses | CD3 Antibody 99 CLDN18.2 Antibody 19 |
CAS Registry Number | NA |
NCIT ID | C187658 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ASP2138 | ASP2138 | 0 | 1 |
ASP2138 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | ASP2138 Fluorouracil Irinotecan Leucovorin Oxaliplatin | 0 | 1 |
ASP2138 + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | ASP2138 Fluorouracil Leucovorin Oxaliplatin Pembrolizumab | 0 | 1 |
ASP2138 + Paclitaxel + Ramucirumab | ASP2138 Paclitaxel Ramucirumab | 0 | 1 |